

1 Transcriptomic Gene Network Profiling and Weak Signal Detection for Prediction 2 of Ovarian Cancer Occurrence, Survival, and Severity by Integrating Bulk and 3 Single-cell RNAseq Data

4
5 Yanming Li^{1,2}, Mihaela Sardu^{1,2}, Devin C. Koestler^{1,2}, Fengwei Yang¹, Md Tamzid Islam¹,
6 Stephan Komladzei¹, Murshalina Akhter¹

7 1. Department of Biostatistics & Data Science, University of Kansas Medical Center. Kansas City, KS 66160. USA.

8 2. The University of Kansas Cancer Center. Kansas City, KS 66160. USA.

9

10 Abstract

11

12 **Background** Ovarian cancer (OC) is a significant gynecological malignancy characterized by its
13 high mortality rate, poor long-term survival rate, and late-stage diagnosis. OC is the 5th leading
14 cause of cancer death among woman and counts 2.1% of all cancer death. OC survival rates
15 are much lower than other cancers that affect woman. Its 5-year survival rate is less than 50%.
16 Only ~17% of OC patients are diagnosed within the early stage. The majority are diagnosed at
17 an advanced stage, making early detection and effective treatment critical challenges. Currently,
18 the identified OC predictive genes are still very sparse, resulting in poor prognostic performance.
19 There exists unmet needs to identify novel prognostic gene biomarkers for OC occurrence,
20 survival, and clinical stages to promote the likelihood of survival and to perform optimal
21 treatments or therapeutic strategies at the earliest stage possible.

22 **Methods** Previous RNAseq analysis on OC focused on detecting differentially expressed (DE)
23 genes only. Many genes, although having weak marginal differential effects, may still exert
24 strong predictive effects on disease outcomes through regulating other DE genes. In this work,
25 we employed a new machine learning method, netLDA, to detect such predictive coregulating
26 genes with weak marginal DE effects for predicting OC occurrence, 5-year survival, and clinical
27 stage. The netLDA detects predictive gene networks (PGN) containing strong DE genes as hub
28 genes and detects coregulating weak genes within the PGNs. The network structures of the
29 detected PGNs along with the strong and weak genes therein are then used in outcome
30 prediction on test datasets.

31 **Results** We identified different sets of signature genes for OC occurrence, survival, and clinical
32 stage. Previously identified prognostic genes, such as *EPCAM*, *UBE2C*, *CHD1L*, *TP53*, *CD24*,
33 *WFDC2*, and *FANCI*, were confirmed. We also identified novel predictive coregulating weak
34 genes including *GIGYF2*, *GNPAT*, *RAD54L*, and *ELL*. Many of the detected predictive gene
35 networks and coregulating weak genes therein overlapped with OC-related biological pathways

36 such as KEGG *tight junction*, *ribosome*, and *cell cycle* pathways. The detection and
37 incorporation of the gene networks and weak genes significantly improved the prediction
38 performance. Cellular mapping of selected feature genes using single-cell RNAseq data further
39 revealed the heterogeneous expression distributions of the signature genes on different cell
40 types.

41 **Conclusions** We established a transcriptomic gene network profile for OC prediction. The novel
42 genes detected provide new targets for early diagnostics and new drug development for OC.

43

44 Introduction

45 Ovarian cancer (OC) is a significant gynecological malignancy characterized by its high
46 incidence rate, poor survival, late-stage diagnosis, and limited treatment options [1,2]. It ranks
47 as one of the most lethal cancers and the 5th leading cause of cancer death among woman [3].
48 It counts 2.1% of all cancer death. Ovarian cancer survival rates are much lower than other
49 cancers that affect woman. Its 5-year survival rate is less than 50%. Its survivors often face
50 physical and psychological challenges, including long-term side effects of treatment, infertility,
51 and anxiety about cancer recurrence. Women diagnosed before the cancer has spread have a
52 much higher five-year survival rate than those diagnosed at a later stage. However, only ~17%
53 of ovarian cancer patients are diagnosed within the early stage. The majority of OC cases are
54 diagnosed at an advanced stage, making early detection and effective treatment critical
55 challenges [4].

56
57 Advances in transcriptomic and genomic research have provided new insights in the discovery
58 of OC oncogenes. Dozens of OC susceptibility genes, such as *BRCA1* [5-8], *BRCA2* [5-7],
59 *EPCAM* [9,10], *TP53* [6,6,7], *CHD1L* [13-15], have been identified over the past decades.
60 However, the sensitivity and specificity using only these genes in prognostics remain
61 suboptimal. Efforts of using machine learning (ML) methods to identify novel gene biomarkers
62 for predicting OC occurrence are still ongoing.

63
64 Compared to cancer occurrence, less research in the literature has been conducted on
65 prediction of OC survival [15,16] and clinical stages [17,18]. It is particularly of scientific interest
66 to investigate whether it is the same or different sets of genes that contribute to OC
67 development and progression (including survival and clinical stages). Identification of novel
68 oncogenes for predicting OC patients' survival and clinical stages would be extremely helpful to
69 promote the likelihood of survival and optimal treatment or therapeutic strategies at the earliest
70 stage as possible, even after the patients being diagnosed of OC.

71
72 Through a series of work, Li et al. [19-23] have shown that in cancer-genomic studies, some
73 genes, even though having weak marginal differential effects (DE), may still exude strong
74 prediction effects on disease outcomes though regulating other strong DE genes. These weak
75 DE genes (or weak genes), together with their coregulated strong genes and the coregulations
76 between them, form predictive gene networks (PDN). Detecting such PDNs and the weak genes
77 therein and integrating them into disease outcome prediction could significantly improve the

78 prediction accuracy. In this project, we used a novel cancer-genomics analytical tool that we
79 recently developed: netLDA – network-based linear discriminant analysis
80 (<https://github.com/lyqglyqg/netLDA>) – to detect predictive gene networks and strong/weak
81 signature genes for predicting OC occurrence, 5-year survival, and clinical stages, using both
82 bulk and single-cell RNAseq (scRNAseq) data.

83
84 By looking at the gene-gene coregulation networks and weak genes, novel signature genes
85 were identified, and the outcome prediction accuracy was significantly increased. The results
86 helped with a better understanding of the underlining dynamic mechanisms of OC development
87 and progression. They may shed light on promotion of precision medicine and new gene
88 therapy development.

89

90 **Materials**

91 **Data acquisition and processing.** Bulk RNAseq and clinical data of 419 OC patients from The
92 Cancer Genome Atlas (TCGA) program and 88 non-disease controls from The Genotype-Tissue
93 Expression (GTEx) project were combined and used as the training data for OC occurrence
94 prediction. Bulk RNAseq data in GSE18521 for 53 OC tumor samples and 10 normal ovary
95 tissue samples from the Gene Expression Omnibus (GEO) database were used as an
96 independent test dataset in the case-control study. There were 11,069 mapped genes on both
97 training and test datasets.

98

99 Bulk RNAseq and survival data from GSE26712 for 195 OC patients were downloaded from
100 GEO and used as the training dataset in the survival prediction. The same types of data for 53
101 OC patients were downloaded from GSE18521 and used as a test dataset. There were 12,645
102 common genes mapped on both datasets. The reason for not using TCGA data as the training
103 data is that TCGA subjects cross a wide range of OC stages, which are heavily confounded with
104 the survival. We did not find a GEO dataset that contains both survival and clinical stage
105 outcomes. Therefore, we used two GEO datasets (both of which contained only late-staged OC
106 patients) as the training and test datasets to alleviate the confounding effect from clinical stages.

107

108 Bulk RNAseq and clinical data from 419 TCGA OC patients and from 77 GSE63885 OC patients
109 were used as the training and test data, respectively, in the OC clinical stage prediction. There
110 were 17,490 mapped genes on both training and test datasets.

111

112 Single-cell RNAseq data of 22,153 cells and 47,913 transcripts from GSE229343 were used in
113 the scRNAseqs data analysis and cellular mapping for the signature genes selected in each
114 study.

115
116 The RNAseq data went through quality control before analysis using R package edgeR [24] or
117 Seurat [25]. For the bulk RNAseq data, genes with counts less than 10 for more than 70% of the
118 samples were removed from analyses. For the scRNAseq data, cells with UMI numbers below
119 500, gene numbers below 300 or greater than 6,000, or mitochondrial-derived UMI counts of
120 more than 15% were considered low-quality and were removed [103].

121

122 **Methods**

123 Three studies were conducted for prediction of different OC outcomes: i) occurrence prediction
124 of OC v.s. healthy, ii) 5-year survival prediction of survival longer than 5 years v.s. shorter than 5
125 years, and iii) severity prediction of clinical stage \leq III v.s. V. The following methods were used in
126 each study.

127

128 **PGN and network-based weak gene selections.** We use the netLDA [20] in both feature
129 selection and outcome prediction. **Figure 1** depicts the major steps of netLDA. First, netLDA
130 selects top strong DE gene as hub genes according to their marginal DE effects. Then for each
131 strong DE gene, netLDA selects its coregulated gene network containing its highly correlated
132 genes (having a Pearson correlation coefficient ρ with $|\rho| > 0.8$). Next, netLDA assigns the
133 following predictive score, or network-adjusted DE effect, to each gene in a selected
134 coregulating network, $PS_i = \sum_{j \in C_i} \Omega_i (\bar{E}_j^{(1)} - \bar{E}_j^{(2)})$, where i and j are gene indices, C_i is the set of
135 genes connected to gene i through a coregulation path, Ω_i is the precision matrix (inverse of
136 the covariance matrix) that characterizes the coregulation information (directions and strengths)
137 between genes in C_i , and $\bar{E}_j^{(1)}$ and $\bar{E}_j^{(2)}$ are the average expression level of gene j in outcome
138 groups 1 and 2, respectively. The predictive score integrates, for each targeted gene, how many
139 other genes it coregulates, the strengths and directions of those regulations, and expression
140 levels of its coregulated genes, as well as expression levels of the targeted gene itself. The
141 most predictive genes are selected according to the strengths of their predictive scores.
142 Selected predictive genes with small marginal DE effects are weak coregulating genes. For
143 prediction, netLDA uses only the selected predictive genes and the coregulation network
144 structures between them to predict outcomes on the test data. **Figure 2** explains the calculation

145 of the predictive scores using toy example data. We also developed permutation tests to
146 evaluate the significance of selected individual genes and PGNs.

147

148 **Prediction performance comparison with competing ML methods.** We compared the
149 prediction performance of netLDA with other commonly used cancer-genomics ML methods
150 including Lasso [26], Ridge [27], ElasticNet [28], XGboost [29], and linear discriminate analysis
151 (LDA) using only the strong genes and ignoring the coregulatory network structures between
152 them. Prediction sensitivities, specificities, and the areas under the receiver operating
153 characteristic curves (ROC) were evaluated to assess the prediction.

154

155 **Kepler-Meijer analysis.** Kepler-Meijer (KM) analysis is a commonly used biomarker validation
156 approach in cancer genomics studies. It compares the survival or KM curves between high- and
157 low- expressed groups of a DE gene [30]. Here we generated KM curves according to the long-
158 and short-term survival groups predicted by using the selected strong and weak genes, and
159 their PGN structures. We compared the KM curves to the ones generated from only using the
160 top strong genes' expression levels.

161

162 **Gene set enrichment analysis.** To validate our identified genes and PGNs from a biological
163 perspective, we conducted gene set enrichment analysis (GSEA) [31], a knowledge-based
164 approach for interpreting transcriptome profiles, using GeneOntology (GO) [32] and Kyoto
165 Encyclopedia of Genes and Genomes (KEGG) [33] pathways. The selected strong/weak genes
166 and PGNs were mapped to the top enriched KEGG pathways to confirm their oncological
167 functionals.

168

169 **Cellular mapping for the selected genes.** To reveal the cellular expression heterogeneity of
170 the selected signature genes, we also performed a scRNAseq analysis for cell type profiling and
171 cellular mapping of the selected genes.

172

173 **Results**

174 **Predictive gene network and network-based gene selections.** Top selected genes in the
175 three studies are listed in **Table 1**. Marginal expression patterns for the selected genes are
176 depicted in **Figure 3**. Top selected PGNs harboring the selected genes were listed in **Table 2**.
177 Topological structures (illustrating the connection topologies) and connection matrices
178 (illustrating the connection strengths) of the PNGs, along with marginal and network-adjusted

179 DE effects of the genes within, were depicted in **Figure 4**. Most of the selected strong genes
180 have both a significant marginal p-value (from marginal tests) and a significant permutation test
181 p-value ($<10^{-4}$, from a network-based test). While majority of the selected weak genes have only
182 a significant permutation test p-value. This demonstrates that integrating of coregulation
183 between genes helps to promote the significance of weak genes in their empirical distributions.
184 For many of the top selected genes, we found literature evidence supporting their associations
185 with OC (last column in **Table 1**). Most of the selected predictive gene networks have significant
186 permutation test p-values (<0.05). Full lists of the selected genes and PGNs are given in the
187 Supplemental Materials.

188
189 We confirmed strong genes previously reported. *SMPDL3B* (marginal p-value= 8.8×10^{-182} ,
190 network-adjusted permutation p-value $< 10^{-4}$) and *SLC34A2* (marginal p-value= 1.9×10^{-190} ,
191 network-adjusted permutation p-value $< 10^{-4}$) were confirmed in the OC occurrence study,
192 *TRAFD1* (marginal p-value = 0.0013, network-adjusted permutation p-value $< 10^{-4}$) and *CHD1L*
193 (marginal p-value = 0.0021, network-adjusted permutation p-value $< 10^{-4}$) were confirmed in the
194 5-year survival study, and *FANCI* (marginal p-value = 0.0016, network-adjusted permutation p-
195 value $< 10^{-4}$) was confirmed in the clinical stage study. Expression of *SMPDL3B* was found
196 related to specific aptamers for ovarian tumors, such as AptaC2 and AptaC4, through molecular
197 docking [34]. *SLC34A2* overexpression was reported related to development and progression of
198 OC, brain cancer, and pancreatic cancer [35]. *TRAFD1* suppression was observed in ovarian,
199 colon, brain, and renal cancers [36]. *CHD1L* overexpression was reported to augment ovarian
200 carcinoma metastasis [15]. *FANCI* has recently been identified as a new ovarian cancer
201 predisposing gene [37,38]. We also discovered some strong genes not been reported before to
202 be associated with OC. For example, *ILDR1* (marginal p-value = 2.1×10^{-204} , network-adjusted
203 permutation p-value $< 10^{-4}$) in OC occurrence study, and *TRAPPC14* (marginal p-value =
204 5.6×10^{-4} , network-adjusted permutation p-value = 2×10^{-4}), *RRP1* (marginal p-value = 0.0019,
205 network-adjusted permutation p-value = 6×10^{-4}), and *ZSWIM8* (marginal p-value = 0.0045,
206 network-adjusted permutation p-value = 6×10^{-4}) in 5-year survival study.

207
208 We also identified weak genes in regulations with the strong genes, such as *PPP1CA* (marginal
209 p-value = 3.3×10^{-9} , network-adjusted permutation p-value $< 10^{-4}$) and *HMGA1* (marginal p-value
210 = 1.0×10^{-57} , network-adjusted permutation p-value $< 10^{-4}$) in occurrence study, *RPS8* (marginal
211 p-value = 0.044, network-adjusted permutation p-value = 0.016), *RPL28* (marginal p-value =
212 0.36, network-adjusted permutation p-value = 0.024), and *RPL31* (marginal p-value = 0.042,

213 network-adjusted permutation p-value = 0.18) in 5-year survival study, and *MAPKAPK5*
214 (marginal p-value = 0.0017, network-adjusted permutation p-value < 10^{-4}) and *BYSL* (marginal
215 p-value = 0.042, network-adjusted permutation p-value < 10^{-4}) in the clinical stage study.
216 *PPP1CA* is a catalytic subunit gene and plays an essential role in the growth of cancer cells
217 [39]. *HMGA1* plays a crucial role in the self-renewal and drug resistance of ovarian cancer stem
218 cells [40]. Ribosomal genes, including *RPS8*, *RPL28*, and *RPL31*, have been recently identified
219 as a novel therapeutic target against high-grade OC [41]. Long noncoding RNA *MAPKAPK5-*
220 *AS1* promotes cancer cell proliferation by cis-regulating the nearby gene *MK5* [42]. *BYSL*
221 expression was reported to be elevated and promote tumor cell growth [43].

222
223 Several novel OC-associated weak genes that have not been reported in the literature before
224 were identified in our study, such as *GIGYF2* (marginal p-value = 0.35, network-adjusted
225 permutation p-value < 10^{-4}), *GNPAT* (marginal p-value = 0.21, network-adjusted permutation p-
226 value < 10^{-4}) and *RAD54L* (marginal p-value = 0.066, network-adjusted permutation p-value <
227 10^{-4}) in the clinical stage study.

228
229 **Table 2** lists the top detected PGNs from each of the three studies. Many of these PGNs are
230 overlapping with the top enriched KEGG and/or GO pathways (also see GSEA results). Genes
231 in a KEGG/GO pathway are biologically validated to be related to systematic biology or
232 oncology. Links between genes in a KEGG/GO pathway are lab-confirmed molecular
233 interaction, reaction, and regulations. Overlapping between our selected PGNs and KEGG/GO
234 pathways can serve as biological evidence of our findings. In the OC occurrence study, one of
235 the two netLDA-detected gene networks contains overlapping genes *CLDN7* (weak), *CLDN4*
236 (weak), *CLDN3* (strong) that are also in the *tight junction* pathway (enrichment p-value= 1.86×10^{-3}),
237 *leukocyte transendothelial migration* pathway (enrichment p-value= 1.76×10^{-3}), and *cell*
238 *adhesion molecules cams* pathway (enrichment p-value= 2.68×10^{-3}). Weak genes *TJP3* and
239 *CRB3*, in the same network, are also overlapped in the *tight junction* pathway. The other
240 predictive gene network selected in OC occurrence study contains two weak genes *PTTG1* and
241 *CDC20* that are overlapping with *cell cycle* pathway (enrichment p-value= 1.85×10^{-5}). In the
242 survival study, one detected predictive gene network is largely overlapped with *ribosome*
243 pathway (enrichment p-value= 1.97×10^{-30}). Twenty-eight out of thirty-one genes in the network
244 are in the *ribosome* pathway, which accounts for 31.8% of the 88 leading genes in the ribosome
245 pathway). In the clinical stage study, multiple detected gene networks overlap with *KEGG cell*
246 *cycle* pathway (enrichment p-value= 4.40×10^{-4}), *KEGG pathways in cancer* (enrichment p-

247 value= 8.12×10^{-3}), *GO DNA replication pathway* (enrichment p-value= 6.91×10^{-9}), *GO DNA*
248 *recombination pathway* (enrichment p-value= 2.09×10^{-8}), and *GO chromosome segregation*
249 *pathway* (enrichment p-value= 1.49×10^{-7}). Genes overlapping with *KEGG cell cycle pathway*
250 include *MCM2* (strong), *CREBBP* (weak), *ABL1* (weak), *PLK1* (weak), *MCM4* (weak), *MCM6*
251 (weak), *BUB1* (weak), *CDC20* (weak), *CCNB1* (weak), *ORC3* (weak), *SMAD2* (weak), *GSK3B*
252 (weak), and *PCNA* (weak). Genes overlapping with *KEGG pathways in cancer* include *PTGS2*
253 (strong), *KRAS* (strong), *WNT6* (strong), *ABL1* (weak), *MTOR* (weak), *SMAD2* (weak), *STK4*
254 (weak), *CREBBP* (weak), *MSH3* (weak), *RXR* (weak), and *GSK3B* (weak). Genes overlapping
255 with *GO DNA replication pathway* include *PRIM1* (strong), *MCM6* (weak), *DDX23* (weak), and
256 *WDHD1* (weak). Genes overlapping with *GO DNA recombination pathway* include *MCM2*
257 (strong), *MCM4* (weak), *HMCES* (weak), and *RUVBL1* (weak). Genes overlapping with *GO*
258 *chromosome segregation pathway* include *BUB1* (weak), *PRC1* (weak), *KIF2C* (weak), *CDC20*
259 (weak), *PLK1* (weak), and *RMI2* (weak).

260
261 **Prediction performance comparison with competing ML methods.** ROC curves in each
262 study are depicted in **Figure 5**. In the occurrence study, all methods gave almost perfect
263 prediction results – area under the ROC curve (AUC) equaling 1 – as all top genes (strong and
264 weak) have much significant differentiating effects compared to top genes in the survival and
265 clinical stage studies. In the survival study, netLDA gave an AUC = 0.91, much higher than using
266 only the strong genes and Lasso/Ridge/elasticNet (0.85-0.87). XGboosting gave a comparable
267 AUC of 0.90. In the clinical stage study, netLDA also gave the highest AUC = 0.65, XGboosting
268 gave an AUC = 0.61, and Lasso/Ridge/elasticNet and LDA using only the strong genes gave an
269 AUC around 0.5, similar to a random guess.

270
271 **KM analysis.** **Figure 6** shows the Kepler-Meijer curves and log-rank test results in the 5-year
272 survival study. **Figure 6 (a)** is for the KM curves and log-rank test between the two netLDA
273 predicted groups using both selected strong/weak genes, and PGN structures. **Figure 6 (b-d)**
274 are KM curves and log-rank tests between high- and low-expression (above and below the
275 median expression value) groups of top three selected strong genes. The two KM curves were
276 more separated, and the log-rank test p-value were more significant between the netLDA
277 predicted groups than those between the expression level groups from a single strong gene,
278 demonstrating the effects of weak genes and PGNs] in improving the classification results.

279

280 **GSEA. Figure 7** shows KEGG and GO pathway enrichment analysis results. The left panels are
281 examples of the top enriched KEGG pathways for each of the three studies. Tight junction
282 pathway was enriched in the OC occurrence study (enrichment p-value = 1.86×10^{-3}), ribosome
283 pathway was enriched in the 5-year survival study (enrichment p-value = 1.97×10^{-30}), cell cycle
284 pathway was enriched in the clinical stage study (enrichment p-value = 4.40×10^{-4}). Many of the
285 weak genes (highlighted in yellow) overlap with these top enriched pathways, confirming that
286 the weak genes play a biological role in the development and progression of OC. A complete list
287 of enriched KEGG pathways is given in the appendix. The right panels in **Figure 7** list the top
288 enriched GO pathways for each study. Top GO pathways enriched in the occurrence study
289 include cell-cell junction organization (enrichment p-value = 4.26×10^{-10}), tight junction assembly
290 pathway (enrichment p-value = 3.55×10^{-9}), and epidermis development pathway (enrichment p-
291 value = 7.00×10^{-9}). Top GO pathways enriched in the survival study include SRP-dependent
292 cotranslational protein targeting to membrane (enrichment p-value = 2.54×10^{-55}) and nuclear-
293 transcribed mRNA catabolic process (enrichment p-value = 2.16×10^{-53}). Top GO pathways
294 enriched in the clinical stage study include DNA replication (enrichment p-value = 6.91×10^{-9})
295 and recombinational repair (enrichment p-value = 1.59×10^{-7}). **Table 3** lists the top enriched
296 KEGG pathways. Lists of top enriched GO pathways are provided in the Supplemental
297 Materials.

298
299 **Cellular mapping for the selected genes using scRNAseq data. Figure 8** shows the cellular
300 distribution of the GSE229343 scRNAseq data and the expression maps of the selected feature
301 genes. In **Figure 8 (a)**, Seurat was first used to identify 28 cell subtype clusters using resolution
302 = 0.2. For OC occurrence study, many genes are expressed on epithelial cells (including strong
303 genes: *CLDN3*, *SLC34A2*, *SMIM22*, *FOLR1*, and weak genes: *CLDN7*, *MAL2*, *SPRINT1*,
304 *PRSS8*, *EHF*, *ELF3*, *KRT8*, *SLPI*, *KRT18*, *EPCAM*, *VAMP8*, *KRT7*, *CLDN4*, *WFDC2*, *CD24*,
305 *MSLN*); on fore/mid/hindgut epithelial cells (including strong genes: *CLDN3*, *SMIM22*, and weak
306 genes: *CLDN7*, *MAL2*, *SPINT1*, *PRSS8*, *ELF3*, *KRT8*, *SLPI*, *KRT18*, *EPCAM*, *KRT7*, *CLDN4*);
307 on cycling neural program/mesenchymal stem cells (including weak genes: *UBE2C*, *CDC20*,
308 *PTTG1*, *UBE2T*); on airway/retinal epi/ciliated cells (including strong genes: *CLDN3*, *SMIM22*,
309 *FOLR1*, and weak genes: *ELF3*, *KRT8*, *UCP2*, *SLPI*, *EPCAM*, *KRT7*, *CLDN4*, *WFDC2*, *CD24*);
310 on myeloid/T cells (including weak genes: *UCP2*, *VAMP8*); and on immature neuron cells
311 (including weak gene *CD24*). For the clinical stage study, many genes are overexpressed on
312 cycling neural program/Mesenchymal stem cells (including weak genes: *CDC20*, *UBE2T*,
313 *NUSAP1*, *CCNB1*, *PLK1*, *ASPM*, *PRC1*, *KIF20A*); on immature neuron cells (including strong

314 gene TUBB2B); and on myeloid cells (including weak gene CD163). For the survival study, as
315 there were very few genes mapped to the scRNAseq GSE229343 gene set, we did not observe
316 a particular cellular express pattern for the selected genes.

317

318 **Summary and Discussion**

319 We confirmed previously identified prognostic genes such as *EPCAM*, *UBE2C*, *CHD1L*, *TP53*¹
320 *CD24* [53], *WFDC2* [53], and *FANCI* associated with OC occurrence, survival, or clinical stage.

321 We identified novel susceptibility strong genes including: *ILDR1* in occurrence study,
322 *TRAPPC14*, *RRP1*, and *ZSWIM8* in the survival study, as well as novel coregulating weak
323 genes including *GIGYF2*, *GNPAT*, *RAD54L*, and *ELL* in the clinical stage study. Our identified
324 gene networks overlapped with KEGG *tight junction*, *leukocyte transendothelial migration*, and
325 *cell cycle* pathways in the occurrence study; with *ribosome* pathway in the survival study; and
326 with *cell cycle* pathway and *pathways in cancer* in the clinical stage study. We found many
327 identified genes particularly expressed on epithelial cells in the occurrence study and on cycling
328 neural program/Mesenchymal stem cells in the clinical stage study. By incorporating gene
329 network structures and weak genes, netLDA significantly improves the prediction performance
330 compared to other ML/DL methods such as Lasso, Ridge, elasticNet, XGboost, and LDA with
331 only strong genes.

332

333 A major contribution of this work is the identification of prognostic oncogenes, especially weak
334 genes in the OC related pathways. The *CLDN* genes (*CLDN7* and *CLDN4* detected in the OC
335 occurrence study) in the *tight junction* pathway and *cell adhesion molecules cams* pathway,
336 which functioning as one of the protective barriers in the epithelial and endothelial cells, were
337 also observed to overexpress on fore/mid/hindgut epithelial cells in the single cell analysis. The
338 weak genes detected in the survival study, mainly ribosomal genes, such as *RPS8* and *RPL28*,
339 overlapping with *ribosome* pathway, which was known to promote protein homeostasis in
340 cancers by fine-tuning protein synthesis and preventing toxic protein aggregation [102]. The
341 *CCN* gene family (*CCNB1* detected in the clinical stage study) and *CDK* genes (*CDK2* within the
342 detected network indexed by *PRIM1* in clinical stage study, see **Table 2**, even though it is not in
343 the final selected weak gene set) are coregulating genes in the *cell cycle* pathway. These
344 regulating weak genes were not reported in the literature, as they were difficult to detect by
345 themselves.

346

347 Although netLDA incorporates gene coregulation network structures into calculating gene
348 differential expressions, it assumes the same network structures (topology, coregulation
349 direction and strength, etc.) between different outcome groups. In real applications, the network
350 structures can be different between groups, in which case a quadratic discriminant analysis
351 might be a better approach. However, accurate and robust inference of different network
352 structures requires large sample sizes per group. Moreover, gene coregulations are usually
353 more stable and robust compared to individual gene expression levels. That is, even individual
354 gene expression levels can vary a lot between different disease groups, cell types, and
355 environments, but the gene-gene coregulation maintains rather stable across the
356 heterogeneous situations. Such robustness in gene networks is critical for assembling a
357 dynamic biology system. Essentially, the network structures inferred by netLDA are the average
358 of different groups when the same network structure assumption is violated.

359
360 Most of the weak genes selected in the OC occurrence study also have strong marginal DE
361 effects. In that sense, they may also be considered as strong genes. The prediction
362 performance is dominated by the top strong genes; therefore, the prediction performance
363 (**Figure 5**) was not much different between netLDA and LDA using only strong genes and other
364 competing methods. The predictive effects of weak genes were manifested in the survival and
365 clinical stage studies, where the marginal DE differential effects of genes are much weaker than
366 that in the occurrence study (**Figure 3** and **Figure 5**). Especially in the clinical stage study, as
367 the strong genes only explained a small portion of the outcome variation on the training data,
368 netLDA dug deeper with more weak genes residing in more predictive networks compared to
369 the occurrence and survival study, in order to accumulate sufficient information to optimize the
370 prediction accuracy on the test data.

371
372 The selected gene sets from the occurrence, survival, and stage studies are non-overlapping.
373 This is mainly because the input gene sets are different for the three studies. Moreover, it also
374 reveals that the OC development and progression may have different underlying molecular
375 mechanisms.

376
377 Since gene expressions in bulk RNAseq data are averaged expressions over different types of
378 cells, DE effects of some genes might be washed out in the averaging. For example, a gene
379 that is significantly differentially expressed only on a particular cell type but not on other cell
380 types might exhibit only a marginally weak DE effect. A gene differentially expressed on two cell


381 types but in different directions will show no marginal DE effect due to signal cancellation. The
382 netLDA is a desired method for detecting such genes. It would be an optimal validation
383 approach to confirm the DE effects of the selected genes using scRNAseq data from both
384 cohorts. Our feature mapping of the selected genes using scRNAseq data helped identify which
385 types of cells the genes are particularly expressed on. Investigators are recommended to
386 conduct DE analyses using scRNAseq data on the identified cell types to further validate the
387 findings.

388

389

390 **Abbreviations**

391	DE	Differentially expressed
392	GEO	Gene Expression Omnibus
393	GO	GeneOntology
394	GSEA	Gene set enrichment analysis
395	GTEX	The Genotype-Tissue Expression project
396	KEGG	Kyoto Encyclopedia of Genes and Genomes
397	KM	Kepler-Meijer
398	LDA	Linear discriminant analysis
399	OC	Ovarian cancer
400	PGN	Predictive gene networks
401	RNAseq	RNA sequencing
402	scRNAseq	single cell RNA sequencing
403	TCGA	The Cancer Genome Atlas



404

405




Figure 2. Detecting weakly differentiating genes but predictive by integrating gene-gene coregulations. **(a)** An example of coregulatory gene network containing five genes. Gene 2 has a strong marginally differentiating effect. The other four genes do not exhibit differentiating effects marginally, as shown in **(c)**. The unidirectional coregulations between the five genes are presented by the edge connections between them. Solid edges represent a positive coregulation and dashed edges represent a negative coregulation. If two genes are not connected by an edge, it means there is no known coregulation between them. The coregulation strength is represented by the width of the edges with the actual values marked aside. **(b)** Connection matrix corresponding to the network in **(a)**. Numbers on the diagonal are the marginal variances for the five genes. Numbers off diagonal are the coregulation strength between genes. **(c)** Marginal expression differences between two groups. Only gene 2 exhibits a strong differential effect. **(d)** The coregulation adjusted differential effects are achieved by multiply the marginal effects by the connection matrix. Genes 3 and 4 also exhibit strong differential effects after the adjustment because of their coregulations with the strong gene 2.

406







Figure 3. Heatmaps of expression of selected genes. **(a)** Cancer occurrence. **(b)** 5-year survival. **(c)** Clinical stage.

407
408







411



412



413






Figure 8. Cellular distribution of expression profile for the selected feature genes. **(a)** Cell type profiling using scRNAseq data GSE229343 of three patients with immature ovarian teratoma. Cellular expression profiles are presented in: **(b-1)** & **(b-2)** for strong and weak genes, respectively, detected in occurrence study, **(c)** for weak gene detected in 5-year survival study, and **(d-1)** & **(d-2)** for strong and weak genes, respectively, detected in clinical stage study.

Table 1. Top selected genes

Gene name	Gene type	Network-adjusted DE	Permutation p-value for network-adjusted DE [†]	Marginal DE	Marginal p-value [‡]	Literature on selected gene
Cancer occurrence prediction						
<i>BRCA2</i> **	strong	--	<0.0001*	1.19	<2.2×10 ⁻¹⁶	5-8
<i>BRCA1</i> **	strong	--	<0.0001*	1.11	<2.2×10 ⁻¹⁶	5-7
<i>PPP1CA</i>	weak	-0.98	<0.0001*	2.21	3.3×10 ⁻⁹	39
<i>UBE2C</i>	weak	0.81	<0.0001*	2.46	3.0×10 ⁻¹³⁴	44-46
<i>SMPDL3B</i>	strong	0.72	<0.0001*	2.50	8.8×10 ⁻¹⁸²	47
<i>ILDR1</i>	strong	0.71	<0.0001*	2.50	2.1×10 ⁻²⁰⁴	
<i>SLC34A2</i>	strong	0.61	<0.0001*	2.43	1.4×10 ⁻¹⁹⁰	48
<i>CLDN7</i>	weak	-0.56	<0.0001*	2.45	8.5×10 ⁻⁹⁶	30
<i>EPS8L1</i>	weak	-0.52	<0.0001*	2.35	2.2×10 ⁻⁶⁰	49
<i>HMGA1</i>	weak	0.51	<0.0001*	2.44	1.0×10 ⁻⁵⁷	50, 51
<i>TMEM238</i>	weak	0.49	<0.0001*	2.43	1.1×10 ⁻¹¹⁶	52
<i>INAVA</i>	weak	0.46	<0.0001*	1.41	4.2×10 ⁻¹²⁵	53
<i>CDC20</i>	weak	0.43	<0.0001*	-0.44	1.3×10 ⁻¹⁰¹	54
<i>SPINT1</i>	weak	-0.38	<0.0001*	4.43	6.7×10 ⁻⁶⁰	55
<i>SMIM22</i>	strong	0.35	<0.0001*	0.87	1.2×10 ⁻¹⁸⁴	56
5-year survival prediction						
<i>TRAFD1</i>	strong	-0.64	<0.0001*	-0.64	0.0013	57
<i>ADPGK</i>	strong	-0.63	<0.0001*	-0.63	6.4×10 ⁻⁵	58
<i>CHD1L</i>	strong	-0.61	<0.0001*	-0.61	0.0021	59-62
<i>PIAS3</i>	strong	-0.60	<0.0001*	-0.60	0.0018	63
<i>TTC31</i>	strong	-0.63	0.0002*	-0.63	1.8×10 ⁻⁴	64
<i>TRAPPC14</i>	strong	-0.61	0.0002*	-0.61	5.6×10 ⁻⁴	
<i>TRPM4</i>	strong	-0.58	0.0003*	-0.58	0.0014	65
<i>TMEM214</i>	strong	-0.56	0.0004*	-0.56	0.0013	66
<i>IMPDH2</i>	strong	0.56	0.0004*	0.56	0.0043	67
<i>CNOT9</i>	strong	-0.56	0.0005*	-0.56	2.6×10 ⁻⁴	
<i>PLD2</i>	strong	-0.55	0.0005*	-0.55	0.0036	68
<i>CTNNBIP1</i>	strong	-0.56	0.0006*	-0.56	9.5×10 ⁻⁴	69
<i>RRP1</i>	strong	-0.55	0.0006*	-0.55	0.0019	
<i>ZSWIM8</i>	strong	-0.55	0.0006*	-0.55	0.0045	
<i>SRPK2</i>	strong	-0.54	0.0006*	-0.54	0.0018	70
<i>FHOD1</i>	strong	-0.54	0.0007*	-0.54	0.0024	71
<i>RBM7</i>	strong	0.54	0.0007*	0.54	<0.0019	72
<i>RPS8</i>	weak	1.45	0.016*	0.47	0.044	73
<i>RPL28</i>	weak	-1.27	0.024	0.22	0.36	74
<i>RPL31</i>	weak	-1.06	0.042	0.29	0.18	75
Clinical stage <IV vs. IV prediction						
<i>MAPKAPK5</i>	weak	-1.63	<0.0001*	-0.57	0.0017	76
<i>BYSL</i>	weak	-1.62	<0.0001*	-0.47	0.042	77, 78
<i>GIGYF2</i>	weak	1.16	<0.0001	0.57	0.35	
<i>TGOLN2</i>	weak	-1.10	<0.0001	0.24	0.073	80
<i>TSC2</i>	weak	0.96	<0.0001	0.35	0.22	81
<i>SNX5</i>	weak	0.91	<0.0001	0.14	0.37	82
<i>PTPRA</i>	weak	0.86	<0.0001	-0.50	0.18	83
<i>GNPAT</i>	weak	0.84	<0.0001	0.23	0.21	
<i>RAD54L</i>	weak	-0.81	<0.0001	0.40	0.066	
<i>FANCI</i>	strong	-0.77	<0.0001*	0.35	0.0016	84, 85
<i>MAP3K7</i>	weak	-0.76	<0.0001*	0.24	0.0045	86
<i>ELL</i>	weak	0.69	<0.0001	-0.42	0.47	
<i>HNRNPLL</i>	weak	-0.67	<0.0001	-0.33	0.057	87
<i>MAP4K3</i>	weak	0.67	<0.0001	0.26	0.50	88
<i>TNRC6A</i>	weak	0.67	<0.0001	-0.11	0.32	89, 90

<i>DDX23</i>	weak	-0.66	<0.0001*	-0.27	0.027	91
<i>CLASP1</i>	weak	0.65	<0.0001	-0.43	0.42	92
<i>WDHD1</i>	weak	-0.64	<0.0001*	0.22	0.026	93, 94
<i>PCNA</i>	weak	-0.64	<0.0001*	-0.59	0.017	95
<i>LRRRC75A</i>	strong	-0.63	<0.0001*	-0.59	0.0016	96
<i>SNRPB</i>	weak	0.62	<0.0001	-0.05	0.13	97
<i>UBN2</i>	weak	0.61	<0.0001	0.80	0.46	98
<i>KIF2C</i>	weak	0.60	<0.0001	-0.14	0.41	99
<i>RAD52</i>	weak	-0.57	<0.0001*	-0.46	0.026	100, 101
<p>† Permutation p-value calculated from permutation test of running the netLDA on the selected gene networks 10,000 times.</p> <p>‡ Marginal p-value calculated from two-sample t test on each individual gene.</p> <p>* Weak gene that has a significant permutation test p-value at level .05 and a significant marginal p-value at level .05.</p> <p>** BRCA1 and BRCA2 genes were not selected by netLDA as strong genes, as they were both filtered out in the data preprocessing by edgeR due to the facts that 84% of samples have counts <10 for BRCA1 and 93% of samples have counts <10 for BRCA2. By default, edgeR requires a minimum count of 10 for samples. We included them in the table because they were widely reported to be associated with ovarian cancer in the literature. Their marginal p-values were achieved from marginal t-tests.</p>						

416

Table 2. Top selected predictive gene networks

Network index hub gene	Network size	Strong gene(s) within network	Connect genes and selected weak genes within network	Permutation network p-value
Cancer occurrence prediction				
<i>ILDR1</i>	31	<i>CLDN3, ILDR1, AP1M2, OVOL2, FOLR1, SMPDL3B</i>	<i>CLDN4, PRSS8, ELF3, EPCAM, ESRP1, KDF1, C1orf210, GRHL2, KRT8, CLDN7, CRB3, MAL2, ST14, SPINT1, TJP3, KRT7, GRB7, MARVELD2, LSR, C6orf132, TMPRSS3, PKP3, MSLN, EPS8L1, TMC4</i>	<0.0001
<i>SLC34A2</i>	29	<i>KLK8, KLK7, SLC34A2, SMIM22</i>	<i>FAM83H, KLK6, EHF, TMEM238, VAMP8, PPP1CA, UCP2, ZDHHC12, RGS19, BSPRY, SAMD10, HMGA1, TPD52, INAVA, KRT18, CXXC5, WFDC2, SLPI, SPINT1-AS1, UBE2C, CD24, CRABP2, PTTG1, UBE2T, CDC20</i>	<0.0001
5-year survival prediction				
<i>RPS3</i>	31	<i>RPS3</i>	<i>RPS8, RPL31, RPS18, RPS24, RPS23, RPL27A, RPS14, RPS29, RPS15A, RPS13, RPL35A, RPS3A, RPL30, RPS15, RPLP1, RPS27, RPL7, RPLP0, RPL18, RPL13A, RPS11, RPL28, RPS19, RPL29, EEF1A1, TPT1, RPS4X, RPS17, RPL41, RPL10</i>	<0.0001
Clinical stage <IV vs. IV prediction				
<i>PRIM1</i>	31	<i>PRIM1, SENP1</i>	<i>CDK2, DDX23, RACGAP1, TUBA1B, HNRNPL, WDR76, HAUS2, MCM6, CTDSPL2, NUSAP1, LMNB1, RFC5, GATC, UNG, RNF34, ANAPC7, PWP1, RMI1, UBQLN1, C9orf64, ZNF367, NAA35, NCBP1, WDHD1, SOCS4, DLGAP5, EXOC5, POLE2, MAPK1IP1L</i>	0.024
<i>PLEKHM3</i>	31	<i>PLEKHM3</i>	<i>SRCAP, HCFC1, POM121, POM121C, YLPM1, SMCR8, ASXL2, BIRC6, HEATR5B, SLC30A6, USP34, PUM2, MED1, CDK12, SYNRG, GPATCH8, FBXL20, KANSL1, MGA, TP53, INO80, VPS39, ZNF106, ZSCAN29, ZBTB40, UBR4, SPEN, CLCN6, MTOR, RBM33</i>	0.032
<i>PDK1</i>	31	<i>PDK1, PPFIA4</i>	<i>HAT1, DYNC112, SP3, ZC3H15, GORASP2, WDR75, DCAF17, TLK1, METTL8, CWC22, PRPF40A, SSB, PRKRA, PLEKHA3, UBE2E3, BZW1, OLA1, SUMO1, ATF2, SF3B1, CREB1, NCKAP1, NFE2L2, HNRNPA3, PFKFB4, HK2, KDM3A, SLC2A1, OXSR1</i>	0.0064
<i>RNFT2</i>	31	<i>RNFT2</i>	<i>SART3, BRAP, NAA25, PRDM4, ATXN2, PTPN11, C12orf43, SPPL3, EIF2B1, DENR, VPS33A, DIABLO, IFT81, USP30, ZNF84, MAPKAPK5, C12orf76, RSRC2, SFSWAP, DDX51, RBM19, FBRSL1, SBNO1, PUS1, KDM2B, CAMKK2, DHX37, ZNF664, ANAPC5, RNF10</i>	<0.0001
<i>IQCC</i>	31	<i>IQCC</i>	<i>S100BPB, RBBP4, TXLNA, BSDC1, KPNA6, ZMYM4, CEP85, EYA3, PDIK1L, EXOSC10, HP1BP3, MFN2, ZMYM1, ZMYM6, IPP, PUM1, REV1, GPBP1L1, SNRNP40, ZCCHC17, EIF3I, PEF1, HDAC1, PPP1R8, TMEM234, PHC2, SRSF4, UBXN11, ZBTB8OS, TRNAU1AP</i>	0.0020
<i>RPRD1A</i>	31	<i>RPRD1A, PIK3C3</i>	<i>ELP2, ZNF24, SLC39A6, ZNF397, ZSCAN30, TRAPPC8, C18orf21, INO80C, RNF138, TPGS2, SNRPD1, IER3IP1, SMAD4, EPG5, SMAD2, DYM, MBD1, ZNF396, KIAA1328, TTC30B, ESCO1, LZTFL1, HDHD2, HNRNPLL, XPO1, MAP4K3, ZFR, DHX9, FBXO11</i>	0.0001
<i>RHOBTB1</i>	31	<i>RHOBTB1</i>	<i>CHSY1, AKAP13, ASB7, MEF2A, ABHD2, TCF12, DPY19L1, KBTBD2, HERPUD2, AZI2, MCFD2, VPS41, KIAA1549, SMO, UBN2, DGKD, TTC26, JARID2, TET1, ACVR2B, SALL2, ZNF660,</i>	<0.0001

			FAM117B, ZNF605, ZNF697 , DCHS1, ADAMTS7, LAMB1, TRAM2, SEMA7A	
KRAS	31	KRAS	FGFR1OP2, KLHL42, ETNK1, MRPS35, TM7SF3, STK38L, RECQL, GOLT1B, STRAP, WBP11, C12orf4, AEBP2, IPO8, DNM1L, ATF7IP, CCDC91, MATR3, ATF6, C2CD5, CMAS, PLEKHA5, PYROXD1, ATN1, TULP3, RPAP3, SCAF11, ATF1 , ASB8, TWF1 , CCNT1	0.019
SLC1A4	31	SLC1A4	IMMT, KCMF1, USP39, CIAO1 , PTCD3 , MRPL35, SMC1A, KDM5C, HUWE1 , MED14, DDX3X, POLA1, VCP, UBAP1 , UBE2R2, TESK1, DNAJA1 , SMU1, ACTR2 , RAB1A, PPP3R1, UGP2, RAB10, AFTPH, TEX261 , PCBP1 , TMEM127, DCTN1, TGOLN2 , STAU1	0.0001
CEP97	31	CEP97	ZBTB11, TBC1D23, PCNP , ZNF143, CGGBP1, ZNF148, SPICE1 , GTF2E1, GSK3B , SLC35A5 , BBX, TFG, SENP7, ZBTB41, NSUN3 , RCOR3, DDX17, WDR11, ARL6 , CPOX, CLDND1, ABHD10 , EFCAB7, LANCL1, CCP110, THUMPD1, KNOP1, COQ7, ERI2, NFATC2IP	0.0028
ZNF669	31	ZNF669	ZNF670, ZNF124, CNST, DESI2, B3GALNT2, SPRTN, AHCTF1, HNRNPU, ARID4B , HEATR1, WDR26, RAB3GAP2, COG2 , GNPAT , TAF5L, IARS2, TSNAX, EXOC8, SH3BP5L , ZNF672, PARP1, ZNF496 , PGBD2, TRIM11, RBBP5, KLHL12 , CDC73, DSTYK , NUCKS1 , RPS6KC1	0.00030
C20orf96	31	C20orf96	SOX12, ZCCHC3, IDH3B , NRSN2, PSMF1, UBOX5 , PCED1A , RBCK1, CRLS1, MRPS26, ITPA, CDS2, DZANK1, EFHC1, BBS5, TASP1, NEK11, NPHP1 , DHX35, CTNBL1, DDX27, CDK5RAP1 , SRSF6, UQCC1, BTBD3, RBBP9, GZF1, PBRM1, SPAST, MSL1	0.011
MYEF2	31	MYEF2	GABPB1, ARPP19 , COPS2, DTWD1 , USP8 , ANP32A, SLTM, SON, RTF1, PRRC2C, DPP8, SP1, TCERG1 , RBM27, DDX46, HNRNPH1, PNN, PRPF38B, SRSF10 , SRRM1, PNRC2 , SFPQ, HNRNPA2B1 , HNRNPDL , HNRNPH3 , YTHDC1, HNRNPK, FUS, SIRT1, CTCF	0.0025
DET1	31	DET1	UNC45A, CRTC3, SEMA4B, SNX1, PEX11A, SCAMP2 , TTC23, TM2D3, SSRP1, LRRC28, CSNK1G1, ARPIN, MRPL46, MRPS11, SEC11A, WDR61, ZFAND6 , HDDC3, SLC24A1 , SPG11, PDCD7, HERC1 , PIAS1, DIS3L , SCAPER, ARIH1, DENND4A , CLPX, FBXO22, MAN2C1	0.017
Bolded genes are the selected genes (including both strong and weak genes) within the network.				

Table 3. Top enriched KEGG pathways and their overlapping selected gene networks

Pathway name	Enrichment pval	Enrichment padj	NES	Pathway size	LeadingEdge genes in pathway	Overlapping with selected genes networks
cc						
KEGG_CEL_L_CYCLE	2.36×10 ⁻⁵	1.38×10 ⁻³	1.79	112	E2F2/CDKN2A/CDC45/TTK/PKMYT1/CDC20/CCNA1/BUB1B/PTTG1/SFN/BUB1/CCNB2/ESPL1/CCNE1/CDK1/CDC6/MAD2L1/CCNB1/PLK1/E2F3/CDKN2B/CND1/MCM2/E2F1/CCNA2/MCM4/CHEK1	CDC20/PTTG1
KEGG_LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION	1.51×10 ⁻³	2.26×10 ⁻²	1.68	83	CLDN6/CLDN3/CLDN9/CLDN16/CLDN4/CLDN7/CLDN10/MMP9/VAV3/VAV1/CXCR4/THY1/CLDN1/CYBA/ITGAL/CYBB/OCLN/RAC2/ITGB2	CLDN3/CLDN4/CLDN7
KEGG_TIGHT_JUNCTION	1.63×10 ⁻³	2.26×10 ⁻²	1.63	97	CLDN6/CLDN3/CLDN9/CLDN16/TJP3/CRB3/CLDN4/CLDN7/CLDN10/MYH14/PPP2R2B/PARD6B/PRKCQ/CLDN1/PRKCZ/CGN/OCLN	CLDN3/TJP3/CRB3/CLDN4/CLDN7
KEGG_CEL_L_ADHESION_MOLECULES_CAMS	2.04×10 ⁻³	2.38×10 ⁻²	1.64	85	CLDN6/CLDN3/CLDN9/CLDN16/CLDN4/CLDN7/CLDN10/HLA-DQA2/CDH1/L1CAM/SDC1/ICOSLG/HLA-DQA1/HLA-DQB1/SELPLG/NRCAM/HLA-DRB5/HLA-DOA/CLDN1/ICAM3/HLA-DMB/HLA-DRA/ITGAL/CADM3/HLA-DPA1/HLA-DRB1/VCAN/HLA-DMA/OCLN/HLA-DPB1/ITGB2/CDH2/CD4/ITGB8/NECTIN1/PTPRC/SDC4/CADM1/ICAM1/SDC3	CLDN3/CLDN4/CLDN7
surv						
KEGG_RIBOSOME	1.97E-30	3.29E-28	3.11	81	MRPL13/RSL24D1/RPS25/RPL36A/RPL10A/RPS3/RPL30/RPS8/RPS12/RPS26/RPL15/RPS23/RPL35A/RPL18A/RPS5/RPL8/RPS15/RPS20/RPL18/RPL36/RPL9/RPL11/FAU/RPS27/RPS15A/RPL10/RPS19/RPS13/RPL27/RPL37/RPS3A/RPS4X/RPS24/RPS29/RPL35/RPL5/RPL23/RPS27A/RPL7/RPS27L/RPS21/RPL10L/RPL34/RPL32/RPL28/RPLP2/RPL14/RPLP1/RPSA/RPL24/RPLP0/RPS6/RPL3/RPL27A/RPL31/RPS18/RPS16/RPS11/RPL19/RPL13/RPL13A/RPS17/RPS10/RPL7A/RPL23A/RPL29/RPS2/RPL41/RPL4/RPL22/RPL38/UBA52/RPS7/RPL12	RPS3/RPL30/RPS8/RPS23/RPL35A/RPS15/RPL18/RPS27/RPS15A/RPL10/RPS19/RPS13/RPS3A/RPS4X/RPS24/RPS29/RPL7/RPL28/RPLP1/RPLP0/RPL27A/RPL31/RPS18/RPS11/RPL13A/RPS17/RPL29/RPL41
Stage						
KEGG_CEL_L_CYCLE	0.00044	0.0072	-1.75	113	TGFB2/CCND2/CDC6/CDC7/E2F1/CDC45/MCM2/CDC25A/ORC3/RBL1/TTK/E2F3/E2F5/CCNE1/MCM3/SMAD4/BUB1B/SMAD2/E2F2/PKMYT1/CCNA2/MAD2L1/CREBBP/WEE1/ESPL1/PCNA/CDK2/SKP2/CCNB2/PLK1/CHEK1/CDC25B/CHAK2/ANAPC7/STAG1/CDKN1C/CCNB1/CDKN1B/ATM/ORC6/RBL2/CDK1	CDK2/ANAPC7/CCNB2/CCNB1/CDK1/SMAD4/SMAD2/TTK/MCM2/MCM3/ORC3/E2F1/RBL1/CCNA2/PLK1/CDC6/BUB1B/PCNA/CREBBP
KEGG_BASIC_CELL_CARCINOMA	0.0016	0.022	-1.87	35	WNT6/FZD5/GLI2/FZD10/GLI3/WNT10A/FZD2/LEF1/WNT2B/STK36	STK36/WNT6
KEGG_PATHWAYS_IN_CANCER	0.008121385	0.075	-1.43	237	WNT6/LAMA1/MMP9/CXCL8/TGFB2/FZD5/GLI2/ARNT2/FZD10/GLI3/BCL2/KRAS/WNT10A/LAMC3/LAMB3/MECOM/E2F1/FZD2/LEF1/CSF3R/WNT2B/E2F3/CCNE1/IGF1R/STK36/SMAD4/PLCG1/FGFR1/SMAD2/LAMB1/E2F2/PIAS2/CREBBP	STK36/CDK2/PLCG1/WNT6/SMAD4/SMAD2/LAMB1/KRAS

					<i>P/CBLB/PDGFB/VHL/CDK2/SKP2/MAPK8/MLH1</i>	<i>E2F1 MAPK8 CREBBP</i>
KEGG_HED GEHOG_S IGNALING_P ATHWAY	0.0145528 4	0.11	-1.68	31	<i>WNT6/LRP2/ZIC2/GLI2/GLI3/WNT10A/ WNT2B/STK36</i>	<i>STK36 WNT6</i>
KEGG_MEL ANOGENES IS	0.021	0.16	-1.48	63	<i>WNT6/FZD5/FZD10/KRAS/WNT10A/PL CB4/ADCY5/GNAO1/FZD2/LEF1/WNT2 B/ADCY7/PLCB1/CREBBP/CREB1/CRE B3L4/ADCY6</i>	<i>WNT6 CREB1 KRAS CREBBP</i>
KEGG_MIS MATCH_RE PAIR	0.062	0.36	-1.51	21	<i>EXO1/RFC4/RFC5/RFC3/PCNA/MLH1/P OLD3/MSH2/LIG1/RFC1/RPA1/MSH3/M SH6</i>	<i>RFC5 MSH3 MSH2/MSH6 EXO1/PCNA</i>
KEGG_GLY COSYLPHO SPHATIDYLI NOSITOL_G PI_ANCHOR BIOSYNTH ESIS	0.064	0.36	-1.51	19	<i>PIGF/PIGG/PIGN/PIGQ/PIGB/PIGU/PIG O/PGAP1/PIGM/PIGT/PIGX/PIGP/PIGV</i>	<i>PIGN</i>
KEGG_DNA REPLICATI ON	0.060	0.36	-1.47	33	<i>DNA2/MCM2/RFC4/RFC5/PRIM2/MCM3 /RFC3/PCNA/POLE/POLD3/LIG1/RFC1/ RPA1/POLA1/FEN1</i>	<i>RFC5 POLE FEN1 MCM2/MCM3 POLA1 PCNA</i>
KEGG_ECM RECEPTO R_INTERAC TION	0.072	0.38	-1.37	59	<i>COL2A1/LAMA1/SV2A/LAMC3/LAMB3/I TGA7/HMMR/LAMB1/SDC1/THBS4</i>	<i>LAMB1 COL2A1</i>

418

419 Reference

- 420
- 421 1. Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. *Nat*
- 422 *Rev Dis Primers*. 2016 Aug 25;2:16061. doi: 10.1038/nrdp.2016.61. PMID: 27558151; PMCID:
- 423 PMC7290868.
- 424 2. Stewart C, Ralyea C, Lockwood S. Ovarian Cancer: An Integrated Review. *Semin Oncol Nurs*.
- 425 2019 Apr;35(2):151-156. doi: 10.1016/j.soncn.2019.02.001. Epub 2019 Mar 11. PMID:
- 426 30867104.
- 427 3. Alexandrova E, Pecoraro G, Sellitto A, Melone V, Ferravante C, Rocco T, Guacci A, Giurato G,
- 428 Nassa G, Rizzo F, Weisz A, Tarallo R. An Overview of Candidate Therapeutic Target Genes in
- 429 Ovarian Cancer. *Cancers (Basel)*. 2020 Jun 4;12(6):1470. doi: 10.3390/cancers12061470. PMID:
- 430 32512900; PMCID: PMC7352306.
- 431 4. National Cancer Institute. Surveillance, Epidemiology, and End Results Program.
- 432 <https://seer.cancer.gov/statfacts/html/ovary.html>.
- 433 5. Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian
- 434 Cancer. 1998 Sep 4 [updated 2023 Sep 21]. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE,
- 435 Bean LJH, Gripp KW, Amemiya A, editors. *GeneReviews®* [Internet]. Seattle (WA): University
- 436 of Washington, Seattle; 1993–2023. PMID: 20301425.
- 437 6. Sánchez-Lorenzo L, Salas-Benito D, Villamayor J, Patiño-García A, González-Martín A. The
- 438 BRCA Gene in Epithelial Ovarian Cancer. *Cancers (Basel)*. 2022 Feb 27;14(5):1235. doi:
- 439 10.3390/cancers14051235. PMID: 35267543; PMCID: PMC8909050.
- 440 7. Casaubon JT, Kashyap S, Regan JP. BRCA1 and BRCA2 Mutations. 2023 Jul 23. In: *StatPearls*
- 441 [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 29262038.
- 442 8. Takaoka M, Miki Y. BRCA1 gene: function and deficiency. *Int J Clin Oncol*. 2018 Feb;23(1):36-
- 443 44. doi: 10.1007/s10147-017-1182-2. Epub 2017 Sep 7. PMID: 28884397.
- 444 9. Tayama S, Motohara T, Narantuya D, Li C, Fujimoto K, Sakaguchi I, Tashiro H, Saya H, Nagano
- 445 O, Katabuchi H. The impact of EpCAM expression on response to chemotherapy and clinical
- 446 outcomes in patients with epithelial ovarian cancer. *Oncotarget*. 2017 Jul 4;8(27):44312-44325.
- 447 doi: 10.18632/oncotarget.17871. PMID: 28574829; PMCID: PMC5546482.
- 448 10. Nunna S, Reinhardt R, Ragozin S, Jeltsch A. Targeted methylation of the epithelial cell adhesion
- 449 molecule (EpCAM) promoter to silence its expression in ovarian cancer cells. *PLoS One*. 2014
- 450 Jan 29;9(1):e87703. doi: 10.1371/journal.pone.0087703. PMID: 24489952; PMCID:
- 451 PMC3906225.
- 452 11. Zhang Y, Cao L, Nguyen D, Lu H. TP53 mutations in epithelial ovarian cancer. *Transl Cancer*
- 453 *Res*. 2016 Dec;5(6):650-663. doi: 10.21037/tcr.2016.08.40. PMID: 30613473; PMCID:
- 454 PMC6320227.
- 455 12. Silwal-Pandit L, Langerød A, Børresen-Dale AL. TP53 Mutations in Breast and Ovarian Cancer.
- 456 *Cold Spring Harb Perspect Med*. 2017 Jan 3;7(1):a026252. doi: 10.1101/cshperspect.a026252.
- 457 PMID: 27815305; PMCID: PMC5204332.
- 458 13. He WP, Guo YY, Yang GP, Lai HL, Sun TT, Zhang ZW, Ouyang LL, Zheng Y, Tian LM, Li XH,
- 459 You ZS, Xie D, Yang GF. CHD1L promotes EOC cell invasiveness and metastasis via the
- 460 regulation of METAP2. *Int J Med Sci*. 2020 Aug 29;17(15):2387-2395. doi: 10.7150/ijms.48615.
- 461 PMID: 32922205; PMCID: PMC7484650.
- 462 14. Soltan MA, Eldeen MA, Eid RA, Alyamani NM, Alqahtani LS, Albogami S, Jafri I, Park MN,
- 463 Alsharif G, Fayad E, Mohamed G, Osman R, Kim B, Zaki MSA. A pan-cancer analysis reveals
- 464 CHD1L as a prognostic and immunological biomarker in several human cancers. *Front Mol*
- 465 *Biosci*. 2023 Mar 23;10:1017148. doi: 10.3389/fmolb.2023.1017148. PMID: 37033447; PMCID:
- 466 PMC10076660.
- 467 15. He WP, Zhou J, Cai MY, Xiao XS, Liao YJ, Kung HF, Guan XY, Xie D, Yang GF. CHD1L
- 468 protein is overexpressed in human ovarian carcinomas and is a novel predictive biomarker for

- 469 patients survival. *BMC Cancer*. 2012 Sep 29;12:437. doi: 10.1186/1471-2407-12-437. PMID:
470 23020525; PMCID: PMC3551745.
- 471 16. Pawar A, Chowdhury OR, Chauhan R, Talole S, Bhattacharjee A. Identification of key gene
472 signatures for the overall survival of ovarian cancer. *J Ovarian Res*. 2022 Jan 20;15(1):12. doi:
473 10.1186/s13048-022-00942-0. PMID: 35057823; PMCID: PMC8780391.
- 474 17. Millstein J, Budden T, Goode EL, Anglesio MS, Talhouk A, Intermaggio MP, Leong HS, Chen S,
475 Elatre W, Gilks B, Nazeran T, Volchek M, Bentley RC, Wang C, Chiu DS, Kommoss S, Leung
476 SCY, Senz J, Lum A, Chow V, Sudderuddin H, Mackenzie R, George J; AOCs Group; Fereday S,
477 Hendley J, Traficante N, Steed H, Koziak JM, Köbel M, McNeish IA, Goranova T, Ennis D,
478 Macintyre G, Silva De Silva D, Ramón Y Cajal T, García-Donas J, Hernando Polo S, Rodriguez
479 GC, Cushing-Haugen KL, Harris HR, Greene CS, Zelaya RA, Behrens S, Fortner RT, Sinn P,
480 Herpel E, Lester J, Lubiński J, Oszurek O, Tołoczko A, Cybulski C, Menkiszak J, Pearce CL,
481 Pike MC, Tseng C, Alsop J, Rhenius V, Song H, Jimenez-Linan M, Piskorz AM, Gentry-Maharaj
482 A, Karpinskyj C, Widschwendter M, Singh N, Kennedy CJ, Sharma R, Harnett PR, Gao B,
483 Johnatty SE, Sayer R, Boros J, Winham SJ, Keeney GL, Kaufmann SH, Larson MC, Luk H,
484 Hernandez BY, Thompson PJ, Wilkens LR, Carney ME, Trabert B, Lissowska J, Brinton L,
485 Sherman ME, Bodelon C, Hinsley S, Lewsley LA, Glasspool R, Banerjee SN, Stronach EA,
486 Haluska P, Ray-Coquard I, Mahner S, Winterhoff B, Slamon D, Levine DA, Kelemen LE,
487 Benitez J, Chang-Claude J, Gronwald J, Wu AH, Menon U, Goodman MT, Schildkraut JM,
488 Wentzensen N, Brown R, Berchuck A, Chenevix-Trench G, deFazio A, Gayther SA, García MJ,
489 Henderson MJ, Rossing MA, Beeghly-Fadiel A, Fasching PA, Orsulic S, Karlan BY, Konecny
490 GE, Huntsman DG, Bowtell DD, Brenton JD, Doherty JA, Pharoah PDP, Ramus SJ. Prognostic
491 gene expression signature for high-grade serous ovarian cancer. *Ann Oncol*. 2020
492 Sep;31(9):1240-1250. doi: 10.1016/j.annonc.2020.05.019. Epub 2020 May 28. PMID: 32473302;
493 PMCID: PMC7484370.
- 494 18. Marchini S, Mariani P, Chiorino G, Marrazzo E, Bonomi R, Fruscio R, Clivio L, Garbi A, Torri V,
495 Cinquini M, Dell'Anna T, Apolone G, Broggin M, D'Incalci M. Analysis of gene expression in
496 early-stage ovarian cancer. *Clin Cancer Res*. 2008 Dec 1;14(23):7850-60. doi: 10.1158/1078-
497 0432.CCR-08-0523. PMID: 19047114.
- 498 19. Li Y, Hong HG, Ahmed SE, Li Y. Weak signals in high-dimension regression: detection,
499 estimation and prediction. *Appl Stoch Models Bus Ind*. 2019;35(2):283-98. Epub 2019/11/02. doi:
500 10.1002/asmb.2340. PubMed PMID: 31666801; PubMed Central PMCID: PMC6821396.
- 501 20. Li Y, Hong HG, Li Y. Multiclass linear discriminant analysis with ultrahigh-dimensional features.
502 *Biometrics*. 2019;75(4):1086-97. Epub 2019/04/23. doi: 10.1111/biom.13065. PubMed PMID:
503 31009070; PubMed Central PMCID: PMC6810714.
- 504 21. Li Y. (2020). A Local-Network Guided Linear Discriminant Analysis for Classifying Lung Cancer
505 Subtypes using Individual Genome-Wide Methylation Profiles. In: Arai, K., Bhatia, R., Kapoor,
506 S. (eds) Proceedings of the Future Technologies Conference (FTC) 2019. FTC 2019. Advances in
507 Intelligent Systems and Computing, vol 1069. Springer, Cham. [https://doi.org/10.1007/978-3-](https://doi.org/10.1007/978-3-030-32520-6_50)
508 030-32520-6_50.
- 509 22. Li Y, Kang J, Wu C, et al. A machine-learning approach for detection of local brain networks and
510 marginally weak signals identifies novel AD/MCI differentiating connectomic neuroimaging
511 biomarkers. *BioRxiv*. doi: <https://doi.org/10.1101/2021.07.29.454368>.
- 512 23. Zhou X, Zhang J, Ding Y, Huang H, Li Y, Chen W. Predicting late-stage age-related macular
513 degeneration by integrating marginally weak SNPs in GWA studies. *Front Genet*.
514 2023;14:1075824. Epub 2023/04/18. doi: 10.3389/fgene.2023.1075824. PubMed PMID:
515 37065470; PubMed Central PMCID: PMC68101437.
- 516 24. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential
517 expression analysis of digital gene expression data. *Bioinformatics*. 2010 Jan 1;26(1):139-40. doi:
518 10.1093/bioinformatics/btp616. Epub 2009 Nov 11. PMID: 19910308; PMCID: PMC2796818.

- 519 25. Satija R, Farrell JA, Gennert D, Schier AF, Regev A. Spatial reconstruction of single-cell gene
520 expression data. *Nat Biotechnol.* 2015 May;33(5):495-502. doi: 10.1038/nbt.3192. Epub 2015
521 Apr 13. PMID: 25867923; PMCID: PMC4430369.
- 522 26. Tibshirani R. Regression Shrinkage and Selection via the Lasso. *Journal of the Royal Statistical*
523 *Society: Series B (Methodological).* 1996; 58, 267-288. <http://www.jstor.org/stable/2346178>.
524 <https://doi.org/10.1111/j.2517-6161.1996.tb02080.x>.
- 525 27. Hilt DE, Seegerist, DW. Ridge, a computer program for calculating ridge regression estimates.
526 1977; doi:10.5962/bhl.title.68934.
- 527 28. Zou H, Hastie T. Regularization and Variable Selection via the Elastic Net. *Journal of the Royal*
528 *Statistical Society, Series B.* 2005; 67 (2): 301–320. CiteSeerX 10.1.1.124.4696.
529 doi:10.1111/j.1467-9868.2005.00503.x. S2CID 122419596.
- 530 29. Chen TQ, Guestrin C. XGBoost: A Scalable Tree Boosting System. In Krishnapuram B, Shah M,
531 Smola AJ, Aggarwal CC, Shen D, Rastogi R (eds.). *Proceedings of the 22nd ACM SIGKDD*
532 *International Conference on Knowledge Discovery and Data Mining, San Francisco, CA, USA,*
533 *2016 August 13-17, 2016.* ACM. pp. 785–794. arXiv:1603.02754. doi:10.1145/2939672.2939785.
534 ISBN 9781450342322. S2CID 4650265.
- 535 30. Liu GM, Zeng HD, Zhang CY, Xu JW. Identification of a six-gene signature predicting overall
536 survival for hepatocellular carcinoma. *Cancer Cell Int.* 2019 May 21;19:138. doi:
537 10.1186/s12935-019-0858-2. PMID: 31139015; PMCID: PMC6528264.
- 538 31. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A,
539 Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-
540 based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A.*
541 2005 Oct 25;102(43):15545-50. doi: 10.1073/pnas.0506580102. Epub 2005 Sep 30. PMID:
542 16199517; PMCID: PMC1239896.
- 543 32. Harris MA, Clark J, Ireland A, Lomax J, Ashburner M, Foulger R, Eilbeck K, Lewis S, Marshall
544 B, Mungall C, Richter J, Rubin GM, Blake JA, Bult C, Dolan M, Drabkin H, Eppig JT, Hill DP,
545 Ni L, Ringwald M, Balakrishnan R, Cherry JM, Christie KR, Costanzo MC, Dwight SS, Engel S,
546 Fisk DG, Hirschman JE, Hong EL, Nash RS, Sethuraman A, Theesfeld CL, Botstein D, Dolinski
547 K, Feierbach B, Berardini T, Mundodi S, Rhee SY, Apweiler R, Barrell D, Camon E, Dimmer E,
548 Lee V, Chisholm R, Gaudet P, Kibbe W, Kishore R, Schwarz EM, Sternberg P, Gwinn M,
549 Hannick L, Wortman J, Berriman M, Wood V, de la Cruz N, Tonellato P, Jaiswal P, Seigfried T,
550 White R; Gene Ontology Consortium. The Gene Ontology (GO) database and informatics
551 resource. *Nucleic Acids Res.* 2004 Jan 1;32(Database issue):D258-61. doi: 10.1093/nar/gkh036.
552 PMID: 14681407; PMCID: PMC308770.
- 553 33. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids Res.* 2000
554 Jan 1;28(1):27-30. doi: 10.1093/nar/28.1.27. PMID: 10592173; PMCID: PMC102409.
- 555 34. Abreu RDS, Antunes D, Moreira ADS, Passetti F, Mendonça JB, de Araújo NS, Sassaro TF,
556 Alberto AVP, Carrossini N, Fernandes PV, Costa MA, Guimarães ACR, Degraive WMS, Waghbi
557 MC. Next Generation of Ovarian Cancer Detection Using Aptamers. *Int J Mol Sci.* 2023 Mar
558 28;24(7):6315. doi: 10.3390/ijms24076315. PMID: 37047289; PMCID: PMC10094455.
- 559 35. Vlasenkova R, Nurgalieva A, Akberova N, Bogdanov M, Kiyamova R. Characterization of
560 SLC34A2 as a Potential Prognostic Marker of Oncological Diseases. *Biomolecules.* 2021 Dec
561 14;11(12):1878. doi: 10.3390/biom11121878. PMID: 34944522; PMCID: PMC8699446.
- 562 36. Sehovic E, Hadrovic A, Dogan S. Detection and analysis of stable and flexible genes towards a
563 genome signature framework in cancer. *Bioinformatics.* 2019 Nov 10;15(10):772-779. doi:
564 10.6026/97320630015772. PMID: 31831960; PMCID: PMC6900328.
- 565 37. Fierheller CT, Alenezi WM, Serruya C, Revil T, Amuzu S, Bedard K, Subramanian DN, Fewings
566 E, Bruce JP, Prokopec S, Bouchard L, Provencher D, Foulkes WD, El Haffaf Z, Mes-Masson
567 AM, Tischkowitz M, Campbell IG, Pugh TJ, Greenwood CMT, Ragoussis J, Tonin PN. Molecular
568 Genetic Characteristics of FANCI, a Proposed New Ovarian Cancer Predisposing Gene. *Genes*

- 569 (Basel). 2023 Jan 20;14(2):277. doi: 10.3390/genes14020277. PMID: 36833203; PMCID:
570 PMC9956348.
- 571 38. Fierheller CT, Guitton-Sert L, Alenezi WM, Revil T, Oros KK, Gao Y, Bedard K, Arcand SL,
572 Serruya C, Behl S, Meunier L, Fleury H, Fewings E, Subramanian DN, Nadaf J, Bruce JP, Bell R,
573 Provencher D, Foulkes WD, El Haffaf Z, Mes-Masson AM, Majewski J, Pugh TJ, Tischkowitz
574 M, James PA, Campbell IG, Greenwood CMT, Ragoussis J, Masson JY, Tonin PN. A functionally
575 impaired missense variant identified in French Canadian families implicates FANCI as a
576 candidate ovarian cancer-predisposing gene. *Genome Med.* 2021 Dec 3;13(1):186. doi:
577 10.1186/s13073-021-00998-5. PMID: 34861889; PMCID: PMC8642877.
- 578 39. Takakura S, Kohno T, Manda R, Okamoto A, Tanaka T, Yokota J. Genetic alterations and
579 expression of the protein phosphatase 1 genes in human cancers. *Int J Oncol.* 2001
580 Apr;18(4):817-24. doi: 10.3892/ijo.18.4.817. PMID: 11251179.
- 581 40. Kim DK, Seo EJ, Choi EJ, Lee SI, Kwon YW, Jang IH, Kim SC, Kim KH, Suh DS, Seong-Jang
582 K, Lee SC, Kim JH. Crucial role of HMGA1 in the self-renewal and drug resistance of ovarian
583 cancer stem cells. *Exp Mol Med.* 2016 Aug 26;48(8):e255. doi: 10.1038/emm.2016.73. PMID:
584 27561949; PMCID: PMC5007643.
- 585 41. Yan S, Frank D, Son J, Hannan KM, Hannan RD, Chan KT, Pearson RB, Sanij E. The Potential
586 of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer. *Int J Mol Sci.* 2017 Jan
587 20;18(1):210. doi: 10.3390/ijms18010210. PMID: 28117679; PMCID: PMC5297839.
- 588 42. Yang T, Chen WC, Shi PC, Liu MR, Jiang T, Song H, Wang JQ, Fan RZ, Pei DS, Song J. Long
589 noncoding RNA MAPKAPK5-AS1 promotes colorectal cancer progression by cis-regulating the
590 nearby gene MK5 and acting as a let-7f-1-3p sponge. *J Exp Clin Cancer Res.* 2020 Jul
591 20;39(1):139. doi: 10.1186/s13046-020-01633-8. Erratum in: *J Exp Clin Cancer Res.* 2022 Dec
592 13;41(1):341. PMID: 32690100; PMCID: PMC7370515.
- 593 43. Gao S, Sha Z, Zhou J, Wu Y, Song Y, Li C, Liu X, Zhang T, Yu R. BYSL contributes to tumor
594 growth by cooperating with the mTORC2 complex in gliomas. *Cancer Biol Med.* 2021 Feb
595 15;18(1):88-104. doi: 10.20892/j.issn.2095-3941.2020.0096. PMID: 33628587; PMCID:
596 PMC7877178.
- 597 44. Li J, Zhi X, Shen X, Chen C, Yuan L, Dong X, Zhu C, Yao L, Chen M. Depletion of UBE2C
598 reduces ovarian cancer malignancy and reverses cisplatin resistance via downregulating CDK1.
599 *Biochem Biophys Res Commun.* 2020 Mar 5;523(2):434-440. doi: 10.1016/j.bbrc.2019.12.058.
600 Epub 2019 Dec 23. PMID: 31875843.
- 601 45. Martínez-Canales S, López de Rodas M, Nuncia-Cantarero M, Páez R, Amir E, Györfy B,
602 Pandiella A, Galán-Moya EM, Ocaña A. Functional transcriptomic annotation and protein-protein
603 interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer.
604 *Cancer Med.* 2018 May;7(5):1896-1907. doi: 10.1002/cam4.1406. Epub 2018 Mar 25. PMID:
605 29575713; PMCID: PMC5943485.
- 606 46. Xiang C, Yan HC. Ubiquitin conjugating enzyme E2 C (UBE2C) may play a dual role involved in
607 the progression of thyroid carcinoma. *Cell Death Discov.* 2022 Mar 24;8(1):130. doi:
608 10.1038/s41420-022-00935-4. PMID: 35332135; PMCID: PMC8948250.
- 609 47. Abreu RDS, Antunes D, Moreira ADS, Passetti F, Mendonça JB, de Araújo NS, Sassaro TF,
610 Alberto AVP, Carrossini N, Fernandes PV, Costa MA, Guimarães ACR, Degraive WMS, Waghbi
611 MC. Next Generation of Ovarian Cancer Detection Using Aptamers. *Int J Mol Sci.* 2023 Mar
612 28;24(7):6315. doi: 10.3390/ijms24076315. PMID: 37047289; PMCID: PMC10094455.
- 613 48. Vlasenkova R, Nurgalieva A, Akberova N, Bogdanov M, Kiyamova R. Characterization of
614 SLC34A2 as a Potential Prognostic Marker of Oncological Diseases. *Biomolecules.* 2021 Dec
615 14;11(12):1878. doi: 10.3390/biom11121878. PMID: 34944522; PMCID: PMC8699446.
- 616 49. Wang Y, Zhang L, Luo X, et al. EPS8L1 promotes migration and metastasis of ovarian cancer by
617 activating Rac1/MAPK signaling pathway via upregulating TIAM2. *Authorea.* December 16,
618 2022. DOI: 10.22541/au.167120661.17798120/v1.

- 619 50. Kim DK, Seo EJ, Choi EJ, Lee SI, Kwon YW, Jang IH, Kim SC, Kim KH, Suh DS, Seong-Jang
620 K, Lee SC, Kim JH. Crucial role of HMGA1 in the self-renewal and drug resistance of ovarian
621 cancer stem cells. *Exp Mol Med*. 2016 Aug 26;48(8):e255. doi: 10.1038/emm.2016.73. PMID:
622 27561949; PMCID: PMC5007643.
- 623 51. Masciullo V, Baldassarre G, Pentimalli F, Berlingieri MT, Boccia A, Chiappetta G, Palazzo J,
624 Manfioletti G, Giancotti V, Viglietto G, Scambia G, Fusco A. HMGA1 protein over-expression is
625 a frequent feature of epithelial ovarian carcinomas. *Carcinogenesis*. 2003 Jul;24(7):1191-8. doi:
626 10.1093/carcin/bgg075. Epub 2003 May 9. PMID: 12807722.
- 627 52. Ye C, Ren S, Sadula A, Guo X, Yuan M, Meng M, Li G, Zhang X, Yuan C. The expression
628 characteristics of transmembrane protein genes in pancreatic ductal adenocarcinoma through
629 comprehensive analysis of bulk and single-cell RNA sequence. *Front Oncol*. 2023 May
630 17;13:1047377. doi: 10.3389/fonc.2023.1047377. PMID: 37265785; PMCID: PMC10229874.
- 631 53. Zhao L, Li Y, Zhang Z, Zou J, Li J, Wei R, Guo Q, Zhu X, Chu C, Fu X, Yue J, Li X. Meta-
632 analysis based gene expression profiling reveals functional genes in ovarian cancer. *Biosci Rep*.
633 2020 Nov 27;40(11):BSR20202911. doi: 10.1042/BSR20202911. PMID: 33135729; PMCID:
634 PMC7677829.
- 635 54. Xi X, Cao T, Qian Y, Wang H, Ju S, Chen Y, Chen T, Yang J, Liang B, Hou S. CDC20 is a novel
636 biomarker for improved clinical predictions in epithelial ovarian cancer. *Am J Cancer Res*. 2022
637 Jul 15;12(7):3303-3317. PMID: 35968331; PMCID: PMC9360218.
- 638 55. Li C, Li W, Zhang Y, Zhang X, Liu T, Zhang Y, Yang Y, Wang L, Pan H, Ji J, Wang C. Increased
639 expression of antisense lncRNA SPINT1-AS1 predicts a poor prognosis in colorectal cancer and
640 is negatively correlated with its sense transcript. *Onco Targets Ther*. 2018 Jul 10;11:3969-3978.
641 doi: 10.2147/OTT.S163883. PMID: 30022840; PMCID: PMC6044340.
- 642 56. Feng H, Gu ZY, Li Q, Liu QH, Yang XY, Zhang JJ. Identification of significant genes with poor
643 prognosis in ovarian cancer via bioinformatical analysis. *J Ovarian Res*. 2019 Apr 22;12(1):35.
644 doi: 10.1186/s13048-019-0508-2. PMID: 31010415; PMCID: PMC6477749.
- 645 57. Sehovic E, Hadrovic A, Dogan S. Detection and analysis of stable and flexible genes towards a
646 genome signature framework in cancer. *Bioinformatics*. 2019 Nov 10;15(10):772-779. doi:
647 10.6026/97320630015772. PMID: 31831960; PMCID: PMC6900328.
- 648 58. Li N, Li H, Wang Y, Cao L, Zhan X. Quantitative proteomics revealed energy metabolism
649 pathway alterations in human epithelial ovarian carcinoma and their regulation by the antiparasite
650 drug ivermectin: data interpretation in the context of 3P medicine. *EPMA J*. 2020 Oct
651 10;11(4):661-694. doi: 10.1007/s13167-020-00224-z. PMID: 33240452; PMCID: PMC7680500.
- 652 59. He WP, Guo YY, Yang GP, Lai HL, Sun TT, Zhang ZW, Ouyang LL, Zheng Y, Tian LM, Li XH,
653 You ZS, Xie D, Yang GF. CHD1L promotes EOC cell invasiveness and metastasis via the
654 regulation of METAP2. *Int J Med Sci*. 2020 Aug 29;17(15):2387-2395. doi: 10.7150/ijms.48615.
655 PMID: 32922205; PMCID: PMC7484650.
- 656 60. Soltan MA, Eldeen MA, Eid RA, Alyamani NM, Alqahtani LS, Albogami S, Jafri I, Park MN,
657 Alsharif G, Fayad E, Mohamed G, Osman R, Kim B, Zaki MSA. A pan-cancer analysis reveals
658 CHD1L as a prognostic and immunological biomarker in several human cancers. *Front Mol*
659 *Biosci*. 2023 Mar 23;10:1017148. doi: 10.3389/fmolb.2023.1017148. PMID: 37033447; PMCID:
660 PMC10076660.
- 661 61. He WP, Zhou J, Cai MY, Xiao XS, Liao YJ, Kung HF, Guan XY, Xie D, Yang GF. CHD1L
662 protein is overexpressed in human ovarian carcinomas and is a novel predictive biomarker for
663 patients survival. *BMC Cancer*. 2012 Sep 29;12:437. doi: 10.1186/1471-2407-12-437. PMID:
664 23020525; PMCID: PMC3551745.
- 665 62. Li Y, He LR, Gao Y, Zhou NN, Liu Y, Zhou XK, Liu JF, Guan XY, Ma NF, Xie D. CHD1L
666 contributes to cisplatin resistance by upregulating the ABCB1-NF- κ B axis in human non-small-
667 cell lung cancer. *Cell Death Dis*. 2019 Feb 4;10(2):99. doi: 10.1038/s41419-019-1371-1. PMID:
668 30718500; PMCID: PMC6362241.

- 669 63. Saini U, Suarez AA, Naidu S, Wallbillich JJ, Bixel K, Wanner RA, Bice J, Kladney RD, Lester J,
670 Karlan BY, Goodfellow PJ, Cohn DE, Selvendiran K. STAT3/PIAS3 Levels Serve as "Early
671 Signature" Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube.
672 *Cancer Res.* 2018 Apr 1;78(7):1739-1750. doi: 10.1158/0008-5472.CAN-17-1671. Epub 2018 Jan
673 16. PMID: 29339537; PMCID: PMC5907493.
- 674 64. Vizeacoumar FJ, Arnold R, Vizeacoumar FS, Chandrashekhar M, Buzina A, Young JT, Kwan JH,
675 Sayad A, Mero P, Lawo S, Tanaka H, Brown KR, Baryshnikova A, Mak AB, Fedyshyn Y, Wang
676 Y, Brito GC, Kasimer D, Makhnevych T, Ketela T, Datti A, Babu M, Emili A, Pelletier L, Wrana
677 J, Wainberg Z, Kim PM, Rottapel R, O'Brien CA, Andrews B, Boone C, Moffat J. A negative
678 genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. *Mol Syst*
679 *Biol.* 2013 Oct 8;9:696. doi: 10.1038/msb.2013.54. PMID: 24104479; PMCID: PMC3817404.
- 680 65. Zhang C, Xu C, Ma C, Zhang Q, Bu S, Zhang DL, Yu L, Wang H. TRPs in Ovarian Serous
681 Cystadenocarcinoma: The Expression Patterns, Prognostic Roles, and Potential Therapeutic
682 Targets. *Front Mol Biosci.* 2022 Jun 24;9:915409. doi: 10.3389/fmolb.2022.915409. PMID:
683 35813831; PMCID: PMC9263218.
- 684 66. Zhang Q, Wang X, Zhang X, Zhan J, Zhang B, Jia J, Chen J. TMEM14A aggravates the
685 progression of human ovarian cancer cells by enhancing the activity of glycolysis. *Exp Ther Med.*
686 2022 Aug 5;24(4):614. doi: 10.3892/etm.2022.11551. PMID: 36160886; PMCID: PMC9468797.
- 687 67. Tian Y, Zhang J, Chen L, Zhang X. The expression and prognostic role of IMPDH2 in ovarian
688 cancer. *Ann Diagn Pathol.* 2020 Jun;46:151511. doi: 10.1016/j.anndiagpath.2020.151511. Epub
689 2020 Mar 23. PMID: 32305001.
- 690 68. Onallah H, Mannully ST, Davidson B, Reich R. Exosome Secretion and Epithelial-Mesenchymal
691 Transition in Ovarian Cancer Are Regulated by Phospholipase D. *Int J Mol Sci.* 2022 Oct
692 31;23(21):13286. doi: 10.3390/ijms232113286. PMID: 36362078; PMCID: PMC9658871.
- 693 69. Li H, Chen L, Tong X, Dai H, Shi T, Cheng X, Sun M, Chen K, Wei Q, Wang M. Functional
694 genetic variants of CTNBP1 predict platinum treatment response of Chinese epithelial ovarian
695 cancer patients. *J Cancer.* 2020 Sep 30;11(23):6850-6860. doi: 10.7150/jca.48218. PMID:
696 33123276; PMCID: PMC7592014.
- 697 70. Caetano MMM, Moreira GA, da Silva MR, Guimarães GR, Santos LO, Pacheco AA, Siqueira
698 RP, Mendes FC, Marques Da Silva EA, Junior AS, Rangel Fietto JL, Saito Â, Boroni M, Bressan
699 GC. Impaired expression of serine/arginine protein kinase 2 (SRPK2) affects melanoma
700 progression. *Front Genet.* 2022 Sep 23;13:979735. doi: 10.3389/fgene.2022.979735. PMID:
701 36212152; PMCID: PMC9537589.
- 702 71. Jiang C, Yuan B, Hang B, Mao JH, Zou X, Wang P. FHOD1 is upregulated in gastric cancer and
703 promotes the proliferation and invasion of gastric cancer cells. *Oncol Lett.* 2021 Oct;22(4):712.
704 doi: 10.3892/ol.2021.12973. Epub 2021 Aug 5. PMID: 34457067; PMCID: PMC8358613.
- 705 72. Li Z, Guo Q, Zhang J, Fu Z, Wang Y, Wang T, Tang J. The RNA-Binding Motif Protein Family in
706 Cancer: Friend or Foe? *Front Oncol.* 2021 Nov 4;11:757135. doi: 10.3389/fonc.2021.757135.
707 PMID: 34804951; PMCID: PMC8600070.
- 708 73. Alexandrova E, Pecoraro G, Sellitto A, Melone V, Ferravante C, Rocco T, Guacci A, Giurato G,
709 Nassa G, Rizzo F, Weisz A, Tarallo R. An Overview of Candidate Therapeutic Target Genes in
710 Ovarian Cancer. *Cancers (Basel).* 2020 Jun 4;12(6):1470. doi: 10.3390/cancers12061470. PMID:
711 32512900; PMCID: PMC7352306.
- 712 74. El Khoury W, Nasr Z. Deregulation of ribosomal proteins in human cancers. *Biosci Rep.* 2021
713 Dec 22;41(12):BSR20211577. doi: 10.1042/BSR20211577. PMID: 34873618; PMCID:
714 PMC8685657.
- 715 75. Wu F, Liu Y, Hu S, Lu C. Ribosomal protein L31 (RPL31) inhibits the proliferation and migration
716 of gastric cancer cells. *Heliyon.* 2023 Jan 20;9(2):e13076. doi: 10.1016/j.heliyon.2023.e13076.
717 PMID: 36816257; PMCID: PMC9936522.
- 718 76. Wang L, Sun L, Liu R, Mo H, Niu Y, Chen T, Wang Y, Han S, Tu K, Liu Q. Long non-coding
719 RNA MAPKAPK5-AS1/PLAGL2/HIF-1 α signaling loop promotes hepatocellular carcinoma

- 720 progression. *J Exp Clin Cancer Res*. 2021 Feb 17;40(1):72. doi: 10.1186/s13046-021-01868-z.
721 PMID: 33596983; PMCID: PMC7891009.
- 722 77. Sha Z, Zhou J, Wu Y, Zhang T, Li C, Meng Q, Musunuru PP, You F, Wu Y, Yu R, Gao S. BYSL
723 Promotes Glioblastoma Cell Migration, Invasion, and Mesenchymal Transition Through the
724 GSK-3 β / β -Catenin Signaling Pathway. *Front Oncol*. 2020 Oct 15;10:565225. doi:
725 10.3389/fonc.2020.565225. PMID: 33178594; PMCID: PMC7593785.
- 726 78. Gao S, Sha Z, Zhou J, Wu Y, Song Y, Li C, Liu X, Zhang T, Yu R. BYSL contributes to tumor
727 growth by cooperating with the mTORC2 complex in gliomas. *Cancer Biol Med*. 2021 Feb
728 15;18(1):88-104. doi: 10.20892/j.issn.2095-3941.2020.0096. PMID: 33628587; PMCID:
729 PMC7877178.
- 730 79. Li Q, Ren CC, Chen YN, Yang L, Zhang F, Wang BJ, Zhu YH, Li FY, Yang J, Zhang ZA. A Risk
731 Score Model Incorporating Three m6A RNA Methylation Regulators and a Related Network of
732 miRNAs-m6A Regulators-m6A Target Genes to Predict the Prognosis of Patients With Ovarian
733 Cancer. *Front Cell Dev Biol*. 2021 Sep 23;9:703969. doi: 10.3389/fcell.2021.703969. PMID:
734 34631700; PMCID: PMC8495156.
- 735 80. Kryczka J, Boncela J. Integrated Bioinformatics Analysis of the Hub Genes Involved in
736 Irinotecan Resistance in Colorectal Cancer. *Biomedicines*. 2022 Jul 16;10(7):1720. doi:
737 10.3390/biomedicines10071720. PMID: 35885025; PMCID: PMC9312838.
- 738 81. Zhu QY, He ZM, Cao WM, Li B. The role of TSC2 in breast cancer: a literature review. *Front*
739 *Oncol*. 2023 May 12;13:1188371. doi: 10.3389/fonc.2023.1188371. PMID: 37251941; PMCID:
740 PMC10213421.
- 741 82. Cai J, Sun M, Hu B, Windle B, Ge X, Li G, Sun Y. Sorting Nexin 5 Controls Head and Neck
742 Squamous Cell Carcinoma Progression by Modulating FBW7. *J Cancer*. 2019 Jun 2;10(13):2942-
743 2952. doi: 10.7150/jca.31055. PMID: 31281471; PMCID: PMC6590026.
- 744 83. Lin C, Xin S, Huang X, Zhang F. PTPRA facilitates cancer growth and migration via the TNF- α -
745 mediated PTPRA-NF- κ B pathway in MCF-7 breast cancer cells. *Oncol Lett*. 2020
746 Nov;20(5):131. doi: 10.3892/ol.2020.11992. Epub 2020 Aug 20. PMID: 32934700; PMCID:
747 PMC7471670.
- 748 84. Fierheller CT, Alenezi WM, Serruya C, Revil T, Amuzu S, Bedard K, Subramanian DN, Fewings
749 E, Bruce JP, Prokopec S, Bouchard L, Provencher D, Foulkes WD, El Haffaf Z, Mes-Masson
750 AM, Tischkowitz M, Campbell IG, Pugh TJ, Greenwood CMT, Ragoussis J, Tonin PN. Molecular
751 Genetic Characteristics of FANCI, a Proposed New Ovarian Cancer Predisposing Gene. *Genes*
752 (Basel). 2023 Jan 20;14(2):277. doi: 10.3390/genes14020277. PMID: 36833203; PMCID:
753 PMC9956348.
- 754 85. Fierheller CT, Guitton-Sert L, Alenezi WM, Revil T, Oros KK, Gao Y, Bedard K, Arcand SL,
755 Serruya C, Behl S, Meunier L, Fleury H, Fewings E, Subramanian DN, Nadaf J, Bruce JP, Bell R,
756 Provencher D, Foulkes WD, El Haffaf Z, Mes-Masson AM, Majewski J, Pugh TJ, Tischkowitz
757 M, James PA, Campbell IG, Greenwood CMT, Ragoussis J, Masson JY, Tonin PN. A functionally
758 impaired missense variant identified in French Canadian families implicates FANCI as a
759 candidate ovarian cancer-predisposing gene. *Genome Med*. 2021 Dec 3;13(1):186. doi:
760 10.1186/s13073-021-00998-5. PMID: 34861889; PMCID: PMC8642877.
- 761 86. Cordas Dos Santos DM, Eilers J, Sosa Vizcaino A, Orlova E, Zimmermann M, Stanulla M,
762 Schrappe M, Börner K, Grimm D, Muckenthaler MU, Kulozik AE, Kunz JB. MAP3K7 is
763 recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation
764 independently of NF- κ B. *BMC Cancer*. 2018 Jun 18;18(1):663. doi: 10.1186/s12885-018-4525-0.
765 PMID: 29914415; PMCID: PMC6006985.
- 766 87. Sakuma K, Sasaki E, Kimura K, Komori K, Shimizu Y, Yatabe Y, Aoki M. HNRNPLL stabilizes
767 mRNA for DNA replication proteins and promotes cell cycle progression in colorectal cancer
768 cells. *Cancer Sci*. 2018 Aug;109(8):2458-2468. doi: 10.1111/cas.13660. Epub 2018 Jul 16. PMID:
769 29869816; PMCID: PMC6113449.

- 770 88. Shi Y, Mo X, Hong S, Li T, Chen B, Chen G. Studying the Role and Molecular Mechanisms of
771 MAP4K3 in Sorafenib Resistance of Hepatocellular Carcinoma. *Biomed Res Int.* 2020 Nov
772 5;2020:4965670. doi: 10.1155/2020/4965670. PMID: 33204699; PMCID: PMC7665914.
- 773 89. Muys BR, Sousa JF, Praça JR, de Araújo LF, Sarshad AA, Anastasakis DG, Wang X, Li XL, de
774 Molfetta GA, Ramão A, Lal A, Vidal DO, Hafner M, Silva WA. miR-450a Acts as a Tumor
775 Suppressor in Ovarian Cancer by Regulating Energy Metabolism. *Cancer Res.* 2019 Jul
776 1;79(13):3294-3305. doi: 10.1158/0008-5472.CAN-19-0490. Epub 2019 May 17. PMID:
777 31101765; PMCID: PMC6606360.
- 778 90. Miśkiewicz J, Mielczarek-Palacz A, Gola JM. MicroRNAs as Potential Biomarkers in
779 Gynecological Cancers. *Biomedicines.* 2023 Jun 13;11(6):1704. doi:
780 10.3390/biomedicines11061704. PMID: 37371799; PMCID: PMC10296063.
- 781 91. Zhao C, Li Y, Qiu C, Chen J, Wu H, Wang Q, Ma X, Song K, Kong B. Splicing Factor DDX23,
782 Transcriptionally Activated by E2F1, Promotes Ovarian Cancer Progression by Regulating
783 FOXM1. *Front Oncol.* 2021 Dec 13;11:749144. doi: 10.3389/fonc.2021.749144. PMID:
784 34966670; PMCID: PMC8710544.
- 785 92. Lisowska KM, Olbryt M, Dudaladava V, Pamuła-Piłat J, Kujawa K, Grzybowska E, Jarzab M,
786 Student S, Rzepecka IK, Jarzab B, Kupryjańczyk J. Gene expression analysis in ovarian cancer -
787 faults and hints from DNA microarray study. *Front Oncol.* 2014 Jan 28;4:6. doi:
788 10.3389/fonc.2014.00006. PMID: 24478986; PMCID: PMC3904181.
- 789 93. Zhang Z, Zhu Q. WD Repeat and HMG Box DNA Binding Protein 1: An Oncoprotein at the Hub
790 of Tumorigenesis and a Novel Therapeutic Target. *Int J Mol Sci.* 2023 Aug 6;24(15):12494. doi:
791 10.3390/ijms241512494. PMID: 37569867; PMCID: PMC10420296.
- 792 94. Xian Q, Zhu D. The Involvement of WDHD1 in the Occurrence of Esophageal Cancer as a
793 Downstream Target of PI3K/AKT Pathway. *J Oncol.* 2022 Apr 5;2022:5871188. doi:
794 10.1155/2022/5871188. PMID: 35422862; PMCID: PMC9005294.
- 795 95. Thomas H, Nasim MM, Sarraf CE, Alison MR, Love S, Lambert HE, Price P. Proliferating cell
796 nuclear antigen (PCNA) immunostaining--a prognostic factor in ovarian cancer? *Br J Cancer.*
797 1995 Feb;71(2):357-62. doi: 10.1038/bjc.1995.72. PMID: 7841053; PMCID: PMC2033602.
- 798 96. Zhu X, You S, Du X, Song K, Lv T, Zhao H, Yao Q. LRRC superfamily expression in stromal
799 cells predicts the clinical prognosis and platinum resistance of ovarian cancer. *BMC Med*
800 *Genomics.* 2023 Jan 18;16(1):10. doi: 10.1186/s12920-023-01435-9. PMID: 36653841; PMCID:
801 PMC9850808.
- 802 97. Wu J, Lu F, Yu B, Wang W, Ye X. The oncogenic role of SNRPB in human tumors: A pan-cancer
803 analysis. *Front Mol Biosci.* 2022 Oct 6;9:994440. doi: 10.3389/fmolb.2022.994440. PMID:
804 36275630; PMCID: PMC9582665.
- 805 98. Dogan B, Gumusoglu E, Ulgen E, Sezerman OU, Gunel T. Integrated bioinformatics analysis of
806 validated and circulating miRNAs in ovarian cancer. *Genomics Inform.* 2022 Jun;20(2):e20. doi:
807 10.5808/gi.21067. Epub 2022 Jun 30. PMID: 35794700; PMCID: PMC9299562.
- 808 99. Wagenbach M, Vicente JJ, Ovechkina Y, Domnitz S, Wordeman L. Functional characterization of
809 MCAK/Kif2C cancer mutations using high-throughput microscopic analysis. *Mol Biol Cell.* 2020
810 Mar 19;31(7):580-588. doi: 10.1091/mbc.E19-09-0503. Epub 2019 Nov 20. PMID: 31746663;
811 PMCID: PMC7202071.
- 812 100. Tong D, Volm T, Eberhardt E, Krainer M, Leodolter S, Kreienberg R, Zeillinger R. Rad52
813 gene mutations in breast/ovarian cancer families and sporadic ovarian carcinoma patients. *Oncol*
814 *Rep.* 2003 Sep-Oct;10(5):1551-3. PMID: 12883740.
- 815 101. Diao Y, Li Y, Wang Z, Wang S, Li P, Kong B. SF3B4 promotes ovarian cancer
816 progression by regulating alternative splicing of RAD52. *Cell Death Dis.* 2022 Feb 24;13(2):179.
817 doi: 10.1038/s41419-022-04630-1. PMID: 35210412; PMCID: PMC8873359.
- 818 102. Challa S, Khulpateea BR, Nandu T, Camacho CV, Ryu KW, Chen H, Peng Y, Lea JS,
819 Kraus WL. Ribosome ADP-ribosylation inhibits translation and maintains proteostasis in cancers.

820 Cell. 2021 Aug 19;184(17):4531-4546.e26. doi: 10.1016/j.cell.2021.07.005. Epub 2021 Jul 26.
821 PMID: 34314702; PMCID: PMC8380725.
822 103. Cao M, Deng Y, Deng Y, Wu J, Yang C, Wang Z, Hou Q, Fu H, Ren Z, Xia X, Li Y, Wang
823 W, Xu H, Liao X, Shu Y. Characterization of immature ovarian teratomas through single-cell
824 transcriptome. Front Immunol. 2023 Mar 3;14:1131814. doi: 10.3389/fimmu.2023.1131814.
825 PMID: 36936909; PMCID: PMC10020330.
826